Folgen
Thorsten Stiewe
Thorsten Stiewe
Zugehörigkeit unbekannt
Bestätigte E-Mail-Adresse bei staff.uni-marburg.de
Titel
Zitiert von
Zitiert von
Jahr
Role of the p53-homologue p73 in E2F1-induced apoptosis
T Stiewe, BM Pützer
Nature genetics 26 (4), 464-469, 2000
4612000
The p53 family in differentiation and tumorigenesis
T Stiewe
Nature Reviews Cancer 7 (3), 165-167, 2007
4092007
The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes
M Luu, S Pautz, V Kohl, R Singh, R Romero, S Lucas, J Hofmann, ...
Nature communications 10 (1), 760, 2019
3272019
Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis
T Stiewe, CC Theseling, BM Putzer
Journal of Biological Chemistry 277 (16), 14177-14185, 2002
2652002
Transactivation-deficient δTA-p73 acts as an oncogene
T Stiewe, S Zimmermann, A Frilling, H Esche, BM Pützer
Cancer research 62 (13), 3598-3602, 2002
2512002
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
E Kadosh, I Snir-Alkalay, A Venkatachalam, S May, A Lasry, E Elyada, ...
Nature 586 (7827), 133-138, 2020
2472020
Gene expression changes in response to E2F1 activation
J Stanelle, T Stiewe, CC Theseling, M Peter, BM Pützer
Nucleic acids research 30 (8), 1859-1867, 2002
2442002
A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism
A Pribluda, E Elyada, Z Wiener, H Hamza, RE Goldstein, M Biton, ...
Cancer cell 24 (2), 242-256, 2013
2392013
Role of p73 in malignancy: tumor suppressor or oncogene?
T Stiewe, BM Pützer
Cell Death & Differentiation 9 (3), 237-245, 2002
2042002
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
M Michaelis, F Rothweiler, S Barth, J Cinatl, M Van Rikxoort, ...
Cell death & disease 2 (12), e243-e243, 2011
1842011
Immune and inflammatory cell composition of human lung cancer stroma
GA Banat, A Tretyn, SS Pullamsetti, J Wilhelm, A Weigert, C Olesch, ...
PLOS one 10 (9), e0139073, 2015
1662015
p53 family members in myogenic differentiation and rhabdomyosarcoma development
H Cam, H Griesmann, M Beitzinger, L Hofmann, R Beinoraviciute-Kellner, ...
Cancer cell 10 (4), 281-293, 2006
1432006
Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer
P Sarode, X Zheng, GA Giotopoulou, A Weigert, C Kuenne, S Guenther, ...
Science advances 6 (23), eaaz6105, 2020
1332020
DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis
K Schlereth, R Beinoraviciute-Kellner, MK Zeitlinger, AC Bretz, M Sauer, ...
Molecular cell 38 (3), 356-368, 2010
1242010
Quantitative TP73 Transcript Analysis in Hepatocellular Carcinomas
T Stiewe, S Tuve, M Peter, A Tannapfel, AH Elmaagacli, BM Pützer
Clinical cancer research 10 (2), 626-633, 2004
1242004
MGA, L3MBTL2 and E2F6 determine genomic binding of the non-canonical Polycomb repressive complex PRC1. 6
B Stielow, F Finkernagel, T Stiewe, A Nist, G Suske
PLoS genetics 14 (1), e1007193, 2018
1112018
Antithetical NFAT c1–Sox2 and p53–miR200 signaling networks govern pancreatic cancer cell plasticity
SK Singh, NM Chen, E Hessmann, J Siveke, M Lahmann, G Singh, ...
The EMBO journal 34 (4), 517-530, 2015
1112015
mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
N Gremke, P Polo, A Dort, J Schneikert, S Elmshäuser, C Brehm, ...
Nature communications 11 (1), 4684, 2020
1092020
Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5
F Vogiatzi, DT Brandt, J Schneikert, J Fuchs, K Grikscheit, M Wanzel, ...
Proceedings of the National Academy of Sciences 113 (52), E8433-E8442, 2016
1082016
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
T Stiewe, TE Haran
Drug Resistance Updates 38, 27-43, 2018
1052018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20